Treatment of Skin Cancer with a Selective Apoptotic-Inducing Curaderm<sup>BEC5</sup>Topical Cream Containing Solasodine Rhamnosides

• 作者: Aruba Cham Bill Cham
• 来源期刊: 临床医学国际期刊(英文)
• 学科: 医学
• 关键词: Skin Cancer BEC SOLAMARGINE Curaderm Apoptosis SOLASODINE Rhamnosides
• 年，卷（期）: 2015,（5）
• 页码范围: 326-333
• 页数: 8页
• 分类号: R73

摘要

Solasodine rhamnosides produced in plants as secondary metabolites, are safe and effective when treating a variety of cancers, including non-melanoma skin cancers. They are cytotoxic against multi-drug resistant tumor cells, stimulate lasting immunity against cancer, are not mutagenic and display anti-mutagenic properties. These antineoplastics, through cellular specific receptor-mediated actions, directly induce apoptosis by triggering extrinsic and intrinsic apoptotic pathways in cancer cells but not normal cells. CuradermBEC5 contains solasodine rhamnosides and is a topical formulation for the treatment of keratoses and non-melanoma skin cancers. The mode of action, together with the selectivity towards cancer cells, with CuradermBEC5 therapy, results in outstanding beneficial outcomes. This study shows graphically and pictorially that CuradermBEC5 seeks and destroys basal cell carcinoma whilst normal skin cells replace the dead cancer cells during therapy, emanating into impressive cosmetic end results. The clinical observations with CuradermBEC5 therapy reveal that initially the lesion size increases over four-fold due to the interaction of CuradermBEC5 with deeper and more lateral tumor cells, followed by a decrease in size, ultimately, resulting in complete elimination of the basal cell carcinoma.